Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
In tumor cells, the serine protease granzyme B is the primary mediator of apoptosis induced by cytotoxic T lymphocytes (CTLs)/natural killer (NK) cells. The human intracellular serpin proteinase inhibitor 9 (PI9) is the only known human protein able to inhibit the proteolytic activity of granzyme B. When present in the cytoplasm of T lymphocytes, PI9 is thought to protect CTLs against apoptosis induced by their own misdirected granzyme B. Based on the speculation that tumors may also express PI9 to escape CTL/NK cell surveillance, immunohistochemical studies on the expression of PI9 in various lymphomas were performed. Ninety-two cases of T-cell non-Hodgkin lymphoma (NHL), 75 cases of B-cell NHL, and 57 cases of Hodgkin lymphomas were stained with a PI9-specific monoclonal antibody. In T-cell NHL, highest PI9 expression was found in the extranodal T-cell NHL. In nearly 90% of enteropathy-type T-cell NHLs and 80% of NK/T-cell, nasal-type lymphomas, the majority of the tumor cells expressed PI9. In nodal T-anaplastic large cell lymphomas and peripheral T-cell lymphomas (not otherwise specified), PI9 expression occurred less frequently. In B-cell NHL, PI9 expression was associated with high-grade malignancy; 43% of diffuse large B-cell lymphomas showed PI9+ tumor cells. Finally, PI9 expression was also found in 10% of Hodgkin lymphomas. This is the first report describing the expression of the granzyme B inhibitor PI9 in human neoplastic cells in vivo. Expression of this inhibitor is yet another mechanism used by tumor cells to escape their elimination by cytotoxic lymphocytes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Young, J. L., Sukhova, G. K., Foster, D., Kisiel, W., Libby, P., & Schönbeck, U. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.9.1535 · Cited by 133
ANNAND, R. R., DAHLEN, J. R., SPRECHER, C. A., DREU, P. D., FOSTER, D. C., MANKOVICH, J. A., TALANIAN, R. V., KISIEL, W., & GIEGEL, D. A. (1999) · Biochemical Journal · doi:10.1042/bj3420655 · Cited by 106
Cited by
Functional significance of the perforin/granzyme cell death pathway
Trapani, J. A., & Smyth, M. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri911 · Cited by 1,291
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
Smith, M. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206939 · Cited by 835
“Expression of protease inhibitor 9 has now documented the existence of this resistance mechanism (Bladergroen et al., 2002).”
BackgroundDeath by a Thousand Cuts: Granzyme Pathways of Programmed Cell Death
Chowdhury, D., & Lieberman, J. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090404 · Cited by 700
Galipeau, J., Krampera, M., Barrett, J., Dazzi, F., Deans, R. J., DeBruijn, J., Dominici, M., Fibbe, W. E., Gee, A. P., Gimble, J. M., et al. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2015.11.008 · Cited by 520
Nanoparticle-Based Immunotherapy for Cancer
Shao, K., Singha, S., Clemente-Casares, X., Tsai, S., Yang, Y., & Santamaria, P. (2015) · ACS Nano · doi:10.1021/nn5062029 · Cited by 470
Metadata
- Authors
- Bladergroen, B. A., Meijer, C. J. L. M., ten Berge, R. L., Hack, C. E., Muris, J. J. F., Dukers, D. F., Chott, A., Kazama, Y., Oudejans, J. J., van Berkum, O., & Kummer, J. A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2002-01-01
- Volume
- 99
- Issue
- 1
- Pages
- 232-237
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2150339137
- Cited by
- 153
- References
- 2
- FWCI
- 8.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? https://app.cochat.ai/papers/10.1182/blood.v99.1.232
- The paper
- Bladergroen, B. A., Meijer, C. J. L. M., ten Berge, R. L., Hack, C. E., Muris, J. J. F., Dukers, D. F., Chott, A., Kazama, Y., Oudejans, J. J., van Berkum, O., & Kummer, J. A. (2002). Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? Blood. https://doi.org/10.1182/blood.v99.1.232
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.